Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Full Evidence Review

Previous related pageVitamin D, Immune Memory Formation and Recall Across Age: Full Evidence ReviewNext related pageVitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Study Summary
Study at a glance

What was studied?

This review compares human B-cell experiments, lupus immune-cell measurements and vaccine studies. B cells produce antibodies, proteins that recognise particular targets, and can contribute to responses when a target appears again. The studies tested active hormone, vitamin D3 or calcifediol, a circulating form requiring activation.

What was found?

Active hormone could increase antibody-secreting cells under one laboratory protocol. Some blood memory B-cell measurements fell in a small study of lupus, an autoimmune disease involving reactions against the body’s own material, without an untreated comparison. The elderly influenza trial and larger CORONAVIT vaccine analysis did not establish an overall benefit. Smaller positive vaccine reports had important problems with group assignment, follow-up or reporting.

What does it mean?

Changes in cell proteins, antibody signals or memory-associated genes are not the same as lasting protection against infection. Lower memory-cell measurements during autoimmune disease do not prove stronger protective memory.

What are the limits?

The studies measured different outcomes. A later study of genes used people from the earlier study, so it was not independent confirmation. Long-lived protective memory remains uncertain. The forms and amounts tested do not establish a personal supplement regimen.

Read the full article below ↓

Vitamin D can alter B-cell differentiation and measured adaptive responses, but that is not the same as establishing durable protective immune memory. Direct human B-cell experiments, a small lupus intervention and vaccine trials measure different parts of this question. The strongest human comparisons do not show a consistent vaccine benefit, while smaller positive reports carry substantial limitations. This review separates those findings rather than treating all antibody or memory-related changes as equivalent. Read the shorter counterpart, Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Study Summary.

The scientific question has several distinct outcomes

B cells can develop into antibody-secreting cells and populations that respond when a target is encountered again. Antibodies are proteins that recognise particular targets. Immune memory also involves T cells and the persistence and quality of responses over time. A temporary rise in antibody signal, a change in circulating memory-cell frequency and fewer infections are different outcomes. The broader physiological context is Vitamin D and Adaptive Immunity.

This review asks what vitamin D signalling does to B-cell function and what the evidence establishes about sustained adaptive responses. It includes four central, distinct study programmes: direct B-cell differentiation, lupus immune phenotypes, influenza vaccination in older adults and the CORONAVIT vaccine substudies. Additional positive vaccine reports are considered with their limitations. Four central studies do not mean four direct tests of long-lived memory formation. [1] [2] [3] [4]

The distinction is especially important for Vitamin D and Immune Memory. Protective memory would ideally be demonstrated through persistent, target-specific cells and functional responses, with appropriate follow-up or protection after re-exposure. The assessed studies generally measured shorter and less complete outcomes. This is a targeted evidence review, not a registered systematic review or a claim that every vaccine setting has been exhaustively resolved.

Direct B-cell differentiation was context-dependent

Treptow and colleagues cultured human naive B cells from healthy donors. Naive cells had not yet acquired the specialised memory characteristics being studied. The investigators used a rich activation and cytokine environment and tested calcitriol, the active vitamin D hormone, alone or with 9-cis retinoic acid. The latter is a distinct vitamin-A-related compound, not another name for vitamin D. [1]

Under the tested conditions, calcitriol could increase differentiation into antibody-secreting plasmablasts and increase immunoglobulin A, or IgA, output. This is a material qualification to a universal statement that vitamin D suppresses B cells. The response depended on the activation sequence and accompanying signals. Results from a combination cannot be attributed entirely to calcitriol or assumed to occur in another culture protocol.

IgA has important roles at mucosal surfaces, but production in a dish did not demonstrate protection at a living gut or airway. The experiments lasted about seven days and did not measure long-lived plasma-cell survival, antibody affinity, protection from infection or persistent antigen-specific memory. The naive-cell fraction was not perfectly pure, and donor sets were small and varied between assays. [1]

The proposed mechanism also has limits. Promoter-binding and transcript measurements supported parts of a regulatory explanation, but a rise in secreted transforming growth factor-beta was not statistically clear. Attempts to block its receptor compromised survival. It would therefore overstate the experiment to claim that this pathway’s necessity was conclusively proved. Nor did every antibody class move in a uniformly favourable direction; the combination could also increase IgE.

This creates a useful connection to Vitamin D and Mucosal Defence. Tissue defence depends on where an antibody is produced, its target and function, not merely the amount of one antibody class. Likewise, Vitamin D and Cytokine Balance provides background on the signals that help shape differentiation. Neither relationship adds an infection outcome to the B-cell experiment.

Fewer memory B cells in lupus did not mean better protective memory

Terrier and colleagues followed twenty women with relatively inactive systemic lupus erythematosus and low vitamin D status during six months of vitamin D3 supplementation. This was an uncontrolled intervention, with stable background treatment, not a placebo-controlled trial. It measured immune phenotypes alongside safety and disease activity. [2]

Some circulating memory B-cell phenotypes declined and regulatory T-cell measures increased. Effects differed between markers and time points. A frequency change did not always coincide with a statistically clear change in absolute cell count. These observations may inform an autoimmune-regulation hypothesis, but there was no concurrent untreated group to separate supplementation from time, medication effects, variation or regression towards typical values.

The meaning of reduced memory B-cell frequency is also context-specific. Reducing a population associated with autoimmune activity would not automatically strengthen memory against infection. The study did not test an antigen-specific response to a vaccine or a later pathogen encounter. Disease activity did not clearly improve, and observing no flares in a small, initially low-activity group does not prove flare prevention. [2]

The paper contains inconsistent baseline vitamin D summaries, so no single disputed mean is used here. This does not erase the intervention, but it limits numerical precision. The research regimen is not a treatment recommendation. The relevant distinction between immune restraint and clinical autoimmune outcomes is introduced in Vitamin D and Immune Tolerance and Vitamin D and Autoimmune Mechanisms.

The elderly influenza trial did not show an overall improvement

Gonçalves-Mendes and colleagues conducted a double-blind placebo-controlled trial in adults older than sixty-five whose 25-hydroxyvitamin D concentration was below 30 nanograms per millilitre. Thirty-eight participants, nineteen per group, were analysed after recruitment ended early. Supplementation preceded influenza vaccination; antibody responses were assessed twenty-eight days afterwards. [3]

Vitamin D status increased, but overall vaccine antibody responses and seroconversion did not improve. Selected strain-specific comparisons favoured placebo. Those findings should remain visible, yet the small sample and multiple outcomes prevent a confident conclusion that vitamin D generally damages vaccine responses. The study was underpowered relative to its original plan, and its initial power calculation concerned another immune endpoint.

The antibody assay measured inhibition of viral haemagglutination, a laboratory property relevant to influenza response. It did not directly count long-lived memory B cells or measure years of protection. A null result at twenty-eight days cannot prove identical responses under every regimen or in every older population. Conversely, the clear biochemical increase cannot be substituted for the absent overall vaccine benefit. [3]

The study contributes to Vitamin D and Immune Ageing because age and immune context matter. It does not show reversal of immune ageing. It also illustrates why the response to correcting a blood marker must be evaluated on the outcome of interest rather than assumed from the marker alone.

CORONAVIT tested vaccine responses within one parent trial

The CORONAVIT vaccine paper reported three nested substudies within one randomized UK trial. The parent trial assigned an offer of vitamin D testing and treatment, or no offer. It was not a blinded placebo comparison. The vaccine analysis included 2,808 eligible participants; binding-antibody data were available for 1,853 and a smaller venous-blood cellular and neutralisation subset involved 101. These are overlapping subsets, not three independent trials. [4]

Supplementation was offered at 800 or 3,200 international units daily when tested 25-hydroxyvitamin D was below 75 nanomoles per litre. These are research methods, not personal dosing guidance. Baseline concentrations were not measured in controls, so the entire vaccine sample cannot be described as a measured-deficient cohort. Excluding controls reporting any supplement use and intervention recipients reporting capsule use less than half the time also limits interpretation as a full intention-to-treat comparison.

The Cox models adjusted for age, sex, education, primary vaccine course, prior infection, vaccination timing and interval, frontline work, household composition, selected medicine use, social contacts and local infection incidence. These adjustments do not restore full intention-to-treat protection after participant selection. No lower breakthrough-infection incidence was established. Adjusted hazard ratios compared with no offer were 1.28, with a 95% confidence interval from 0.89 to 1.84, and 1.17, from 0.81 to 1.70, for the two offered doses. An interval including one does not establish an exact zero effect; these estimates nevertheless do not support a demonstrated protective benefit. [4]

The tested antibody and cellular responses did not show a benefit after accounting for multiple comparisons. Severe clinical outcomes were too few to resolve. Follow-up extended only to roughly six months after the second vaccine dose, not years of immune-memory persistence. Different vaccines, selected substudies and the small cellular sample limit generalisation.

A positive calcifediol programme requires substantial qualification

Bhat and colleagues reported a prospective comparison among 580 recipients of the ChAdOx1 vaccine. A later Saroha paper analysed gene-expression responses in twenty-four selected participants from that programme. The companion is not independent confirmation. Importantly, the parent supplementary methods state that participants could choose intervention or placebo. Despite the controlled-trial title, allocation was self-selected rather than randomized. [5] [8]

The intervention was calcifediol, the circulating precursor, not cholecalciferol or active calcitriol. The reported 50-microgram daily regimen ran for six months from the first vaccine dose in the exposed and unexposed groups, and three months from the second dose in the second-dose group. These different schedules should not be silently combined. The study does not establish that this regimen is appropriate for general use.

The parent reported stronger antigen-stimulated proliferation and fewer probable COVID-19 episodes, while anti-spike antibody titres were similar. Self-selection, open-label symptom enquiry and loss to follow-up limit causal interpretation. Clinical follow-up was available for 414 of 580 participants. Probable illness was not uniformly laboratory-confirmed infection, and selected infection comparisons did not show the same result. [5]

The companion reported changes in genes associated with memory responses, particularly at three months, with several returning towards baseline by six months. Bulk blood-cell gene expression does not directly establish which memory cells formed, whether they persisted or whether they prevented infection. High achieved blood 25-hydroxyvitamin D concentrations and incomplete assessment of all possible safety outcomes also prevent casual reassurance about the regimen. Industry involvement and disclosed author interests further warrant careful interpretation, without implying that they alone invalidate the data. [8]

Smaller positive reports do not settle the disagreement

Cesur and colleagues studied thirty-three young women after COVID-19 vaccination. The title describes a randomized trial, but the principal paper does not adequately explain allocation or concealment; there was no placebo, and registration was retrospective. The supplemented group began with a lower antibody assay signal. It had a higher signal at four weeks, but the between-group comparison at eight weeks was not significant. A final increase within the treated group is not a demonstrated final treatment advantage. [6]

The assay signal was not a neutralisation, memory-cell or clinical-protection endpoint. Dose descriptions were inconsistent. These features make the report a low-confidence positive lead rather than a decisive counterweight to the larger trial. Its existence should be acknowledged without presenting every result as equally reliable.

Fateh and colleagues reported another positive immunoglobulin result after COVID-19 and subsequent vaccination. Important reporting problems include differing enrolment and analysis denominators, substantial group imbalances and retrospective registration. The antibody assay’s target and calibration are insufficiently clear for its reported grams-per-litre measurement to be treated as validated anti-spike protection. No direct immune-memory or clinical efficacy endpoint was established. [7]

These are reasons for very low interpretive confidence, not allegations of misconduct. Their methodological limitations give these reports less evidential weight. A balanced assessment considers reported positive evidence while explaining why its design and measurements restrict what it can change in the conclusion.

What remains unresolved about lasting memory?

MeasurementWhat it can showWhat it does not automatically show
Plasmablast differentiation and IgA secretionShort-term B-cell activity in a defined culturePersistent protective memory in people
Circulating memory B-cell phenotypeA population’s measured characteristics or frequencyBetter response to infection
Antibody titre or assay signalOne measured antibody response at one timeNeutralisation, durability or clinical protection
Memory-related genesA molecular response in sampled cellsFormation of functional long-lived memory
Breakthrough infectionA clinical outcome under the tested conditionsWhich memory mechanism caused the outcome

The selected evidence supports context-dependent B-cell and adaptive responses. The larger randomized vaccine evidence does not demonstrate a consistent benefit, and the smaller positive reports do not establish durable protective memory. Vitamin D and Immune Modulation concerns regulation of response magnitude; it should not be confused with increasing every response or guaranteeing protection.

The remaining gap is specific: convincing evidence would need to connect the vitamin D exposure, target-specific memory-cell function, persistence and clinically meaningful protection. Current cell phenotypes, transient genes and short antibody measurements cannot jointly manufacture that missing result. This review therefore supports careful mechanistic interpretation and uncertainty about durable benefit, rather than a supplement recommendation or a claim that every possible adaptive effect has been excluded.

Primary sources

[1] Treptow S et al. 9-cis Retinoic acid and 1.25-dihydroxyvitamin D3 drive differentiation into IgA+ secreting plasmablasts in human naïve B cells. European journal of immunology. 2021;51(1):125-137. DOI: 10.1002/eji.202048557. PMID: 33107588.

[2] Terrier B et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis research & therapy. 2012;14(5):R221. DOI: 10.1186/ar4060. PMID: 23075451.

[3] Goncalves-Mendes N et al. Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Frontiers in immunology. 2019;10:65. DOI: 10.3389/fimmu.2019.00065. PMID: 30800121.

[4] Jolliffe DA et al. Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial. Nutrients. 2022;14(18):3821. DOI: 10.3390/nu14183821. PMID: 36145196.

[5] Bhat S et al. Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial. The Journal of infection. 2023;86(5):e120-e122. DOI: 10.1016/j.jinf.2023.03.004. PMID: 36889512.

[6] Cesur F et al. Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial. Vaccine. 2023;41(17):2860-2867. DOI: 10.1016/j.vaccine.2023.03.046. PMID: 37003908.

[7] Fateh HL et al. The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial. Clinical nutrition research. 2023;12(4):269-282. DOI: 10.7762/cnr.2023.12.4.269. PMID: 37969936.

[8] Saroha HS et al. Calcifediol boosts efficacy of ChAdOx1 nCoV-19 vaccine by upregulating genes promoting memory T cell responses. NPJ vaccines. 2024;9(1):114. DOI: 10.1038/s41541-024-00909-w. PMID: 38902265.

Related reading

Original sources

Source

Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation

In this prospective study, we evaluated the safety and the immunological effects of vitamin D supplementation (100 000 IU of cholecalciferol per week for 4 weeks, followed by 100 000 IU of cholecalciferol per month for 6 months.) in 20 SLE patients with hypovitaminosis D.

Publication details

[2] Terrier B et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis research & therapy. 2012;14(5):R221. DOI: 10.1186/ar4060. PMID: 23075451.

Read more →
Source

Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial

This randomized placebo-controlled double-blind trial investigated whether Vit-D supplementation in deficient elderly persons could improve influenza seroprotection and immune response.

Publication details

[3] Goncalves-Mendes N et al. Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Frontiers in immunology. 2019;10:65. DOI: 10.3389/fimmu.2019.00065. PMID: 30800121.

Read more →
Source

Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial

Sub-study 1 (n = 2808) investigated the effects of vitamin D supplementation on the risk of breakthrough SARS-CoV-2 infection following two doses of SARS-CoV-2 vaccine.

Publication details

[4] Jolliffe DA et al. Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial. Nutrients. 2022;14(18):3821. DOI: 10.3390/nu14183821. PMID: 36145196.

Read more →
Source

Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial

Published in The Journal of infection (2023).

Publication details

[5] Bhat S et al. Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial. The Journal of infection. 2023;86(5):e120-e122. DOI: 10.1016/j.jinf.2023.03.004. PMID: 36889512.

Read more →
Source

The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial

Published in Clinical nutrition research (2023).

Publication details

[7] Fateh HL et al. The Effect of Vit-D Supplementation on the Side Effect of BioNTech, Pfizer Vaccination and Immunoglobulin G Response Against SARS-CoV-2 in the Individuals Tested Positive for COVID-19: A Randomized Control Trial. Clinical nutrition research. 2023;12(4):269-282. DOI: 10.7762/cnr.2023.12.4.269. PMID: 37969936.

Read more →
Source

Calcifediol boosts efficacy of ChAdOx1 nCoV-19 vaccine by upregulating genes promoting memory T cell responses

In our previous study eligible subjects were supplemented with calcifediol, a direct precursor to the biologically active form of vitamin D, calcitriol with an objective to enhance the immunogenicity of the COVISHIELD vaccine.

Publication details

[8] Saroha HS et al. Calcifediol boosts efficacy of ChAdOx1 nCoV-19 vaccine by upregulating genes promoting memory T cell responses. NPJ vaccines. 2024;9(1):114. DOI: 10.1038/s41541-024-00909-w. PMID: 38902265.

Read more →